Hammersmith Imanet

Hammersmith Imanet was a premier clinical research organization and imaging center specializing in Positron Emission Tomography (PET). Originally established as a joint venture between Amersham Health and Imperial College London, it became a key part of GE Healthcare's research infrastructure. The company focused on the development and application of novel radiopharmaceuticals to support drug discovery and clinical diagnosis. By providing advanced molecular imaging services, Hammersmith Imanet enabled pharmaceutical companies to evaluate drug distribution, target occupancy, and therapeutic efficacy in vivo. Its expertise spanned oncology, neurology, and cardiology, contributing significantly to the validation of molecular targets in early-stage clinical trials.